Collagen as a clinical target: nonoperative treatment of Dupuytren's disease.
about
Rehabilitation after surgery for Dupuytren's ContractureWhat are we measuring? A critique of range of motion methods currently in use for Dupuytren's disease and recommendations for practiceIn vitro study of novel collagenase (XIAFLEX®) on Dupuytren's disease fibroblasts displays unique drug related propertiesType-1 Collagen differentially alters beta-catenin accumulation in primary Dupuytren's Disease cord and adjacent palmar fascia cellsThe emerging role of Clostridium histolyticum collagenase in the treatment of Dupuytren disease.Dupuytren's contracture unfolded.Late complications of clinical clostridium histolyticum collagenase use in Dupuytren's diseaseClinical outcomes following collagenase injections compared to fasciectomy in the treatment of Dupuytren's contractureRecent Surgical and Medical Advances in the Treatment of Dupuytren's Disease - A Systematic Review of the LiteratureDupuytren's: a systems biology disease.Management of Dupuytren's disease--clear advice for an elusive conditionDelayed manipulation after collagenase clostridium histolyticum injection for Dupuytren contracture.Minimally invasive partial fasciectomy for Dupuytren's contractures.Collagenase Dupuytren Contracture: Achieving Single Treatment Success with a Hand Therapist-Based Protocol.Optimal functional outcome measures for assessing treatment for Dupuytren's disease: a systematic review and recommendations for future practice.Increased CCT-eta expression is a marker of latent and active disease and a modulator of fibroblast contractility in Dupuytren's contracture.Extracellular matrix and airway smooth muscle interactions: a target for modulating airway wall remodelling and hyperresponsiveness?Examining the efficacy and maintenance of contracture correction after collagenase clostridium histolyticum treatment for Dupuytren's disease.The fascia of the limbs and back--a review.Collagenase clostridium histolyticum in Dupuytren's contracture: a systematic reviewDupuytren's disease: current state of the artCollagenase clostridium histolyticum for Dupuytren's contracture.A systematic review of outcomes of fasciotomy, aponeurotomy, and collagenase treatments for Dupuytren's contracture.Early outcomes of a sequential series of 144 patients with Dupuytren's contracture treated by collagenase injection using an increased dose, multi-cord technique.Molecular mechanisms and treatment strategies for Dupuytren's disease.Dupuytren's Contracture: A Bibliometric Study of the Most Cited Papers.Surgical findings in the treatment of Dupuytren's disease after initial treatment with clostridial collagenase (Xiaflex).Unité Rhumatologique des Affections de la Main (URAM) scale: development and validation of a tool to assess Dupuytren's disease-specific disability.Long-Term Effects of the Collagenase of the Bacterium Clostridium histolyticum for the Treatment of Capsular Fibrosis After Silicone Implants.Feedback inhibition of high TGF-beta1 concentrations on myofibroblast induction and contraction by Dupuytren's fibroblasts.
P2860
Q24245910-8EA9E31F-57D4-4E63-A366-145D3267B04EQ28067091-52C6B550-7BAE-4D71-9597-377530F74630Q28481259-63C6B900-8077-4BEE-A9AB-4D7ADD660CE4Q33471772-3AAA3CF7-4254-43EA-8BE0-7F7990D004F4Q34153159-7950E93F-4733-48A2-8EB8-94C777C74CE8Q34367026-539FAAA4-9195-466D-ABC9-4ABDE9A4BADEQ34389581-EBA8ACC8-0688-4CB0-B61F-26433332B932Q35661449-EF441F48-B683-415B-9EDA-F4668E4592D7Q35800728-1A100EE3-60D7-4562-A865-CA945828A5C3Q35840713-C01616D3-A4B3-4003-9C49-382FDA4CA5B5Q35968773-0DD92D7C-80CF-4598-8E98-09789D2A429BQ36001782-D8800B84-BA6C-4D17-9966-DC0D5EB17121Q36427744-F677166F-7C9F-421F-9533-8EC9C5DE3B7CQ36653340-513F5FED-AB03-4E2E-84DA-1EBE56DAD29BQ36799416-18AD312A-F24A-4FA0-B633-82B88012A9F8Q36927329-D41C3658-11F3-45D9-AB84-4EBB0CB19216Q36933209-372AEED5-31C7-4B4F-8481-3F1730EB9EB0Q37099422-7A5B658B-5903-4D78-B492-5E79A0151FDBQ37376401-1540BCC6-2092-4653-BD01-45E83975B2E0Q37451519-3C9391CE-DF12-4779-A4D2-8FD9AEDC9AF4Q37591761-F57DCF9A-D02D-490D-A8F5-C89DD8E9FEE2Q37776261-EE52B7D0-B86C-46CF-9E0E-690A7DF4778BQ38040111-6744ABFA-0B30-4544-903F-8FFB98BECFA4Q38201930-9C841BD0-0E94-4632-A63A-8A28BCA86C6BQ39835520-29FD7F42-694D-427F-B75F-5C048D78DDC5Q40521021-30C5D3E6-9E18-4CA4-801D-B3008264873FQ44207914-D33E1B36-40D7-4F37-91D1-F481482DD98DQ48823408-BEFF58BF-B777-4D90-9163-8D1B9A03A880Q50993790-BDF8FDDB-ACE5-4CD4-9661-B8FA5A96215CQ51154314-D511337A-D249-49CA-B244-B3A5373D194A
P2860
Collagen as a clinical target: nonoperative treatment of Dupuytren's disease.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Collagen as a clinical target: nonoperative treatment of Dupuytren's disease.
@ast
Collagen as a clinical target: nonoperative treatment of Dupuytren's disease.
@en
Collagen as a clinical target: nonoperative treatment of Dupuytren's disease.
@nl
type
label
Collagen as a clinical target: nonoperative treatment of Dupuytren's disease.
@ast
Collagen as a clinical target: nonoperative treatment of Dupuytren's disease.
@en
Collagen as a clinical target: nonoperative treatment of Dupuytren's disease.
@nl
prefLabel
Collagen as a clinical target: nonoperative treatment of Dupuytren's disease.
@ast
Collagen as a clinical target: nonoperative treatment of Dupuytren's disease.
@en
Collagen as a clinical target: nonoperative treatment of Dupuytren's disease.
@nl
P2093
P356
P1476
Collagen as a clinical target: nonoperative treatment of Dupuytren's disease.
@en
P2093
Lawrence C Hurst
Marie A Badalamente
Vincent R Hentz
P304
P356
10.1053/JHSU.2002.35299
P577
2002-09-01T00:00:00Z